News & Events
June 2, 2022
Biochemist, Biotechnology Expert to Lead C-Path’s Type 1 Diabetes Consortium
C-Path has named Elnaz Atabakhsh, Ph.D., as Executive Director of its Type 1 Diabetes Consortium (T1DC). Atabakhsh joined C-Path this May with extensive experience in the biotechnology and biomarker development industry. Her previous work focused on biomarker discovery and screening, cancer genetics and cell therapies for autoimmune disorders, aimed at supporting patients unable to be served by traditional therapeutics. Atabakhsh has extensive experience in and a passion for leading patient-oriented, mission-driven collaborations that include diverse representation from the scientific and medical communities.
June 1, 2022
C-Path Receives Largest Data Transfer to Date from UK’s National Neonatal Research Database
C-Path has received fully anonymized electronic patient record (EPR) data from the National Neonatal Research Database (NNRD). This is part of efforts to better understand and find treatments for a chronic lung disease which frequently affects premature infants. This initiative, funded by a grant from the U.S. Food and Drug Administration (FDA), is being executed through a neonatal pilot project within C-Path’s International Neonatal Consortium (INC). It is the first time C-Path has received EPR data from the United Kingdom and includes data from a network of nearly 200 hospitals in England.
May 31, 2022
FSHD Society and Critical Path Institute Collaborate to Collect Clinical Trial Data
The FSHD Society, a research-focused patient advocacy nonprofit dedicated to bringing treatments to patients affected by facioscapulohumeral muscular dystrophy (FSHD), has partnered with Critical Path Institute (C-Path) to facilitate the integration of clinical trial data from the control arm of various FSHD-related clinical studies into C-Path’s Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP ®). These data will come from several companies that have sponsored clinical trials in FSHD.
April 28, 2022
C-Path to Lead Novel Pre-Consortium Framework for Optimizing the Rare and Orphan Medical Product Lifecycle
C-Path, in collaboration with one of the industry’s prominent rare and orphan (R&O) thought leaders, Maryna Kolochavina, Pharm.D., Ph.D., today announced the launch of unique pre-consortium collaboration, bringing together industry leaders and stakeholders to accelerate and standardize key constructs for the efficient development, approval and access to R&O medical products.
April 14, 2022
Longtime Pharmaceutical Executive to Lead C-Path’s Sickle Cell Disease Consortium
Critical Path Institute (C-Path) has named Sergey Rakhilin, Ph.D., as Executive Director of its Critical Path for Sickle Cell Disease (CP-SCD) Consortium.
Dr. Rakhilin joined C-Path after working in the pharmaceutical industry for 15 years. His work focused on various aspects of drug development, from target identification to clinical studies and biomarker analysis. He has contributed to the development of several treatments for muscle atrophy, hematological, and neurodegenerative diseases.